Literature DB >> 1536954

High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.

A H Sarris1, S Kempin, E Berman, J Michaeli, C Little, M Andreeff, T Gee, D Straus, B Gansbacher, D Filippa.   

Abstract

We determined the incidence and complications of disseminated intravascular coagulation (DIC) at presentation and during remission induction of previously untreated adults with acute lymphoblastic leukemia (ALL) or de novo Philadelphia chromosome-positive ALL (PCALL) seen at Memorial Hospital between January 1, 1978 and December 31, 1989. DIC was diagnosed in the presence of (1) low fibrinogen (less than or equal to 160 mg/dL), (2) prolonged prothrombin time (PT) and falling fibrinogen, or (3) prolonged PT and positive fibrin split products (FSP). L-Asparaginase was not used during remission induction. Among adequately screened patients with ALL, DIC was detected in 7 of 58 (12%) before initiation of chemotherapy and in 35 of 45 (78%) during remission induction. DIC was not simply the result of infection because clinical and laboratory signs of infection were absent in 16 patients, whereas only 2 of the 22 febrile patients with DIC had positive cultures. Among the 38 patients with DIC at presentation or during remission induction, serious complications were seen in 13 in temporal association with DIC (pulmonary embolus in one, sagittal sinus thrombosis in three, and serious hemorrhage in nine) and were major factors in the deaths of three patients. Among the 10 patients with thorough screening but no evidence of DIC there was only one hemorrhage during the same time interval. In patients with PCALL, DIC was detected in 9% at presentation and in 80% during remission induction. We conclude that DIC is rare at presentation but common during remission induction of adult ALL and PCALL and may be associated with significant thrombotic and hemorrhagic complications. We suggest daily screening for DIC during the first 14 days of remission induction. The treatment of DIC in ALL and PCALL should be a subject of future clinical studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536954

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

2.  Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Robert S Makar; Darko Antic; Jerrold H Levy; James D Douketis; Jean M Connors; Marc Carrier; Jeffrey I Zwicker
Journal:  J Thromb Haemost       Date:  2020-12       Impact factor: 5.824

Review 3.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.

Authors:  Arturo J Martí-Carvajal; Vidhu Anand; Ivan Solà
Journal:  Cochrane Database Syst Rev       Date:  2015-06-24

4.  Prediction model for mortality after intracranial hemorrhage in patients with leukemia.

Authors:  Farshid Dayyani; Sarah Schellhorn Mougalian; Kiran Naqvi; Jianqin Shan; Farhad Ravandi; Jorge Cortes; Jeffrey Weinberg; Elias Jabbour; Stefan Faderl; William Wierda; Deborah Thomas; Susan O'Brien; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2011-04-20       Impact factor: 10.047

5.  Underlying Disorders, Clinical Phenotypes, and Treatment Diversity among Patients with Disseminated Intravascular Coagulation.

Authors:  Hiroyuki Ohbe; Kazuma Yamakawa; Kohei Taniguchi; Kojiro Morita; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  JMA J       Date:  2020-09-23

6.  Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation.

Authors:  Hideki Uchiumi; Takafumi Matsushima; Arito Yamane; Noriko Doki; Hiroyuki Irisawa; Takayuki Saitoh; Tohru Sakura; Takahiro Jimbo; Hiroshi Handa; Norifumi Tsukamoto; Masamitsu Karasawa; Shuichi Miyawaki; Hirokazu Murakami; Yoshihisa Nojima
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 7.  Identifying oncological emergencies.

Authors:  Achuta K Guddati; Nilay Kumar; Ankur Segon; Parijat S Joy; Creticus P Marak; Gagan Kumar
Journal:  Med Oncol       Date:  2013-07-20       Impact factor: 3.064

8.  Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation.

Authors:  Kazutaka Takagi; Toshiki Tasaki; Takahiro Yamauchi; Hiromichi Iwasaki; Takanori Ueda
Journal:  Case Rep Hematol       Date:  2011-08-02

Review 9.  Understanding and treating solid tumor-related disseminated intravascular coagulation in the "era" of targeted cancer therapies.

Authors:  Felice Vito Vitale; Giuseppe Sa Longo-Sorbello; Stefano Rotondo; Francesco Ferrau
Journal:  SAGE Open Med       Date:  2017-12-21

10.  Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.

Authors:  Michael Schwameis; Andreas Schober; Christian Schörgenhofer; Wolfgang Reinhard Sperr; Herbert Schöchl; Karin Janata-Schwatczek; Erol Istepan Kürkciyan; Fritz Sterz; Bernd Jilma
Journal:  Crit Care Med       Date:  2015-11       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.